These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36437752)

  • 1. Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future.
    Li L; Liu HT; Teng YX; Deng ZJ; Zhang GL; Su JY; Ma L; Zhong JH
    Expert Opin Investig Drugs; 2022 Nov; 31(11):1151-1167. PubMed ID: 36437752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TKIs in combination with immunotherapy for hepatocellular carcinoma.
    Stefanini B; Ielasi L; Chen R; Abbati C; Tonnini M; Tovoli F; Granito A
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):279-291. PubMed ID: 36794716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
    Gordan JD; Kennedy EB; Abou-Alfa GK; Beg MS; Brower ST; Gade TP; Goff L; Gupta S; Guy J; Harris WP; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Knox JJ; Kortmansky J; Leaf A; Remak WM; Shroff RT; Sohal DPS; Taddei TH; Venepalli NK; Wilson A; Zhu AX; Rose MG
    J Clin Oncol; 2020 Dec; 38(36):4317-4345. PubMed ID: 33197225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
    Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
    Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
    Gordan JD; Kennedy EB; Abou-Alfa GK; Beal E; Finn RS; Gade TP; Goff L; Gupta S; Guy J; Hoang HT; Iyer R; Jaiyesimi I; Jhawer M; Karippot A; Kaseb AO; Kelley RK; Kortmansky J; Leaf A; Remak WM; Sohal DPS; Taddei TH; Wilson Woods A; Yarchoan M; Rose MG
    J Clin Oncol; 2024 May; 42(15):1830-1850. PubMed ID: 38502889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in pharmacotherapeutics for hepatocellular carcinoma.
    Cerrito L; Santopaolo F; Monti F; Pompili M; Gasbarrini A; Ponziani FR
    Expert Opin Pharmacother; 2021 Jul; 22(10):1343-1354. PubMed ID: 33637024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
    Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors.
    Piñero F; Silva M; Iavarone M
    World J Gastroenterol; 2020 Apr; 26(16):1888-1900. PubMed ID: 32390700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.
    Cabibbo G; Reig M; Celsa C; Torres F; Battaglia S; Enea M; Rizzo GEM; Petta S; Calvaruso V; Di Marco V; Craxì A; Singal AG; Bruix J; Cammà C
    Liver Cancer; 2022 Jan; 11(1):75-84. PubMed ID: 35222509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
    Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
    Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving therapeutic strategies for advanced hepatocellular carcinoma.
    Qureshi A; Michel M; Lerner J; Dasanu CA
    Expert Opin Pharmacother; 2021 Dec; 22(18):2495-2506. PubMed ID: 34252328
    [No Abstract]   [Full Text] [Related]  

  • 17. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?
    Rizzo A; Dadduzio V; Ricci AD; Massari F; Di Federico A; Gadaleta-Caldarola G; Brandi G
    Expert Opin Investig Drugs; 2022 Apr; 31(4):371-378. PubMed ID: 34167433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
    Furuse J; Ueno M; Ikeda M
    Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
    Woo HY; Yoo SY; Heo J
    Expert Opin Pharmacother; 2017 Jan; 18(1):35-44. PubMed ID: 27849399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma.
    Sharma R; Motedayen Aval L
    Front Immunol; 2021; 12():652007. PubMed ID: 33790915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.